Refining the Use of Radiation

Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer (CEO), Telix Pharmaceuticals

- 

BUSINESS PERSON OF THE YEAR 2024

Dr Christian Behrenbruch founded Telix Pharmaceuticals in 2015, along with Andreas Kluge, with an aim to create a truly integrated radiopharmaceutical company, enabled by precision medicine. With over two decades of radiopharmaceuticals experience and a strong track record in global healthcare and biotechnology entrepreneurship and technology commercialisation, Dr Behrenbruch has brought a unique blend of technical expertise and executive leadership to guide Telix as it furthers the next stage of growth. Dr Behrenbruch has a strong focus on purpose and values-leadership and is well versed in all aspects of running a publicly listed company as both the Chief Executive Officer (CEO) and Director in the United States and Australia.

Under his leadership, Telix is developing targeted radiation therapies with the potential to be efficacious as stand-alone treatments or as complements to existing treatment modalities, addressing areas of high unmet medical need.

Illuccix (kit for the preparation of Ga-68 Glu-urea-Lys(ahx)-hbedCC Injection), also known as 68Ga-PSMA-11 injection), Telix's lead prostate cancer imaging agent having received US Food and Drug Administration (FDA), Australian Therapeutic Goods Administration (TGA), and Health Canada approval, has been a key driver in the company's business growth.